ERAS Program Improves Recovery of HCC Patient Undergoing Hepatectomy

feng xiaobin

Status: Unknown

Conditions: HCC

Treatments: Procedure: ERAS Program; Procedure: Traditional treatment

Study type: Interventional

Funder types: Other

Identifiers

NCT03104920

SWHB016

Details and patient eligibility

About

The worldwide introduction of multimodal enhanced recovery programs has also changed perioperative care in patients who undergo liver resection. This study will be performed to assess a comprehensive care package for patients with hepatocellular carcinoma (HCC) undergoing hepatectomy with the aim of minimal physiological disturbance in the peri-operative period. Peri-operative opioid-sparing analgesia with few gastrointestinal (GI) effects and reduced requirement for intravenous fluid therapy, early ambulation and promoted GI function recovery were centered to this plan.

Full description

The first ERAS program was introduced by Kehlet in the 1990's. ERAS programs were initially implemented in colorectal surgery and have found their way into general clinical practice, including orthopedic, vascular, and thoracic surgery. In the field of liver surgery, cohort studies have been conducted and randomized trials have confirmed the feasibility and safety of enhanced recovery programs in resectional liver surgery.

Randomized studies have suggested that ERAS optimization may contribute in decreasing stay in hospital after surgery. We hypothesized that opioid-sparing preemptive and post-operative multimodal analgesia plus other ERAS items would effectively accelerate patient recovery, who receiving hepatectomy. We focus on some fundamental variables that impact normal physiology and enhanced-recovery after surgery: fasting, opioid-sparing, exception of an abdominal drain, and GI function rehabilitation. We draw attention to the fact that time to recovery is a far more important and better outcome measure than time to discharge from the hospital.

GI function protection and restore was of importance as the respect of ERAS. Traditionally, perioperative fasting is consisted of being nil by mouth from midnight before surgery and fasting postoperatively until recovery of bowel function. Those empirical practices persist despite emerging evidence revealing that excessive fasting results in negative outcomes and delayed recovery. Strong and assistant evidence exists for minimization of perioperative fasting for 2-hour preoperative fast after clear fluids and for early oral food and fluids intake postoperatively. Also, current study should be applying anti-ileus prophylaxis and abolition of bowel preparation.

Optimizing pain control was regarding as one of the ultimate goal of ERAS program: pain and risk free surgery. Surgical incisions evoke nociceptors by inducing local inflammatory response. The consequence hyperalgesia has been considered to be target of well pain controlling. Here, the multimodal opioid-sparing approaches have been emphasized. A regimen composed by TAP, local anesthesia, PCA, and systematic anti-inflammatory would be performed in order to reduce surgical stress responses.

Several studies have reported that mobilization within 24h of colon surgery was an independent predictor of shorter rehabilitation period. In current study, early postoperative enforced mobilization with specific target will be implemented.

The purpose of this study is twofold. On the one hand examine the scientific evidence that exists today on the most important elements of an ERAS program and present preliminary results of the implementation of a program ERAS in West China.

Enrollment: 392 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent;
• Elective partial hepatectomy for HCC;
• No major concomitant surgical procedures such as bowl or bile duct resection;
• Tumors restricted in hepatic segment: II, III, IVb, VI and VII;
• Child-Pugh Class A/B liver function status；
• ECGO scores = 0

Exclusion criteria

• Tumor thrombi in portal vein;
• Tumor size >10cm;
• History of uncontrolled ascites, hepatic encephalopathy, and varices bleeding;
• ICG>14%;
• Concurrent with other malignant disease;
• Multiple organ dysfunctions;
• Viral infectious disease besides HBV and HCV;
• Diabetes Mellitus;
• Ruptured hepatocellular carcinoma;
• History of treatment such as TACE, RFI, PEI.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

392 participants in 2 patient groups

ERAS program

Experimental group

Description:

We give an ERAS pathway, which comprises of optimized management of diet, mobilization, analgesia and GI function recovery for patients with HCC.

Treatment:

Procedure: ERAS Program

Traditional treatment

Active Comparator group

Description:

We give routine clinic practices for the treatment of HCC.

Treatment:

Procedure: Traditional treatment